Advertisement
Advertisement
NPCE
Neuropace, Inc. Common Stock
14.27
USDSponsored
-0.38
-2.60%
Apr 10, 15:59 UTC -4
Closed
After-Market
14.26
-0.01
-0.10%
NPCE Earnings Reports
Positive Surprise Ratio
NPCE beat 13 of 20 last estimates.
65%
Next Report
Date of Next Report
May 07, 2026
Estimate for Q1 26 (Revenue/ EPS)
$22.08M
/-$0.23
Implied change from Q4 25 (Revenue/ EPS)
-16.97%
/+187.50%
Implied change from Q1 25 (Revenue/ EPS)
-1.98%
/+9.52%
Neuropace, Inc. Common Stock earnings per share and revenue
On Mar 03, 2026, NPCE reported earnings of -0.08 USD per share (EPS) for Q4 25, beating the estimate of -0.15 USD, resulting in a 48.22% surprise. Revenue reached 26.59 million, compared to an expected 25.29 million, with a 5.14% difference. The market reacted with a +3.84% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 9 analysts forecast an EPS of -0.23 USD, with revenue projected to reach 22.08 million USD, implying an increase of 187.50% EPS, and decrease of -16.97% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
AngioDynamics, Inc.
Report Date
Apr 02, 2026 For Q3 26
Estimate
-$0.11
Actual
$0.02
Surprise
+117.83%
LENSAR, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.07
Actual
-$0.12
Surprise
-68.07%
Xtant Medical Holdings, Inc.
Report Date
Mar 31, 2026 For Q4 25
Estimate
$0.00
Actual
$0.00
Surprise
+100.00%
Adagio Medical Holdings, Inc Common Stock
Report Date
Mar 27, 2026 For Q4 25
Estimate
-$0.31
Actual
-$0.16
Surprise
+49.40%
PAVmed Inc. Common Stock
Report Date
Mar 27, 2026 For Q4 25
Estimate
-$5.50
Actual
-$5.52
Surprise
-0.22%
American Shared Hospital Services
Report Date
Mar 31, 2026 For Q4 25
Estimate
$0.02
Actual
-$0.09
Surprise
-545.54%
NexGel, Inc Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.09
Actual
-$0.12
Surprise
-30.72%
ENDRA Life Sciences Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$1.25
Actual
-$3.26
Surprise
-159.84%
FAQ
What were Neuropace, Inc. Common Stock's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Neuropace, Inc. Common Stock reported EPS of -$0.08, beating estimates by 48.22%, and revenue of $26.59M, 5.14% above expectations.
How did the market react to Neuropace, Inc. Common Stock's Q4 2025 earnings?
The stock price moved up 3.84%, changed from $16.13 before the earnings release to $16.75 the day after.
When is Neuropace, Inc. Common Stock expected to report next?
The next earning report is scheduled for May 07, 2026.
What are the forecasts for Neuropace, Inc. Common Stock's next earnings report?
Based on 9
analysts, Neuropace, Inc. Common Stock is expected to report EPS of -$0.23 and revenue of $22.08M for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement